Search results
How sham patents are hurting the pharma industry
Pharmaceutical Technology via Yahoo Finance· 11 hours ago“[The Orange Book] is a very unusual system that has greatly encouraged generic companies to challenge patents,” Singla continues. Singla specialises in...
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Zacks via Yahoo Finance· 1 day agoThe earnings season for the drug/biotech sector is now in its final lap, with two S&P 500 companies,...
Earnings call: Assertio Holdings reports growth and CEO search progress By Investing.com
Investing.com· 8 hours agoThe company highlighted a significant 32% quarter-over-quarter growth in Rolvedon sales and the...
New Jersey drug company to provide cash, naloxone to Delaware in latest opioid settlement
Delaware Online | The News Journal via Yahoo News· 22 hours agoNew Jersey-based drug manufacturer Amneal Pharmaceuticals has become the latest company to reach a settlement agreement with Delaware and other states for ...
Cost and Piqray: Financial assistance options, savings, more
Medical News Today· 1 day agoThe cost of the drug, with and without insurance, can depend on several factors, such as whether...
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Zacks via Yahoo Finance· 7 hours agoThis, in turn, prompts collaboration deals with either pharma or biotech bigwigs, wherein sales are...
Indian drugmaker Lupin misses quarterly profit estimates as costs rise
Reuters via Yahoo Finance· 1 day agoIn March, Lupin decided to carve out its trade generics business in India into a separate unit, Lupin Life Sciences...average estimate of 5.16 billion rupees, according to ...
William Blair Commentary- Large-Cap Growth: Managing Risk and Seeking Consistent Returns
GuruFocus.com via Yahoo Finance· 1 hour agoGiven that this dynamic negatively impacts a company's long-term growth potential, we have been...
US challenges ‘bogus’ patents on Ozempic and other drugs in effort to spur competition
KSAN - KLST San Angelo· 7 days agoWASHINGTON (AP) — Federal regulators are challenging patents on 20 brand-name drugs, including the...
India's Dr Reddy's expects healthy products pipeline in North America for FY25
Reuters· 4 hours ago, opens new tab expects a healthy products pipeline in its key North American market in the fiscal year 2024-25, the generic drugmaker said on Tuesday, after it reported a ...